Earnings Ahead

BMRN - BioMarin Pharmaceutical Inc.

76.22 -3.37 -4.23

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

About

Profile

BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to


Headquarters

Novato, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

BMRN



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M
  • BioMarin appoints Alexander Hardy as president and chief executive officer
  • BioMarin Pharmaceutical Q3 2023 Earnings Preview
  • Bernstein upgrades BioMarin to market perform, citing valuation
  • FDA approves use of BioMarin drug Voxzogo in children under 5
  • BioMarin a market perform at Raymond James due to growth concerns
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line
  • BioMarin Pharmaceutical Q2 2023 Earnings Preview
  • BioMarin upgraded at BMO after FDA nod for hemophilia A therapy
  • BioMarin granted FDA nod for hemophilia A gene therapy
  • Eli Lilly, Humana among best health care names in defensive environment - BofA
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M
  • BioMarin Pharmaceutical Q1 2023 Earnings Preview
  • What is behind biotech M&A resurgence?
  • FDA to back accelerated approval pathway for gene therapies
  • BioMarin seeks FDA nod to expand use of its Voxzogo treatment in children under five
  • BioMarin's Roctavian gets FDA action date extended to end of June
  • BridgeBio soars 55% after Phase 2 data for achondroplasia candidate
  • BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M
  • BioMarin Pharmaceutical Q4 2022 Earnings Preview
Date Price Open High Low Vol Change
Nov 20 62.56 61.97
62.69
61.61
1.1M 0.95%
Nov 19 61.97 61.57
62.03
61.15
1.9M 0.06%
Nov 18 61.93 63.15
63.52
61.4
2.1M -2.35%
Nov 15 63.42 66.05
66.05
63.22
1.7M -3.32%
Nov 14 65.6 66.37
67
65.53
1.4M -1.59%
 
Nov 13 66.66 66.18
67
66
1.5M 0.80%
Nov 12 66.13 65.96
66.69
65.8
1.2M -0.36%
Nov 11 66.37 67.21
67.95
66.32
905K -1.04%
Nov 8 67.07 66.76
67.44
66.67
1.1M 0.19%
Nov 7 66.94 66.32
67.3
65.75
1.4M 1.19%
Nov 6 66.15 67.31
67.64
65.79
2.0M 0.17%
Nov 5 66.04 66.23
66.23
65.45
1.6M 0.05%
Nov 4 66.01 66.24
66.59
65.56
2.0M -0.89%
Nov 1 66.6 65.7
66.81
65.6
1.6M 1.08%
Oct 31 65.89 66.68
66.92
65.35
1.8M -1.18%
Oct 30 66.68 69.67
69.67
65.78
2.8M -4.62%
Oct 29 69.91 69.78
70.56
69.2
1.8M -0.31%
Oct 28 70.13 69.92
70.71
69.6
1.5M 0.57%
Oct 25 69.73 70.68
70.98
69.66
1.1M -0.94%
Oct 24 70.39 70.05
70.98
69.58
1.1M 0.59%
Oct 23 69.98 70.23
70.37
69.39
1.5M -0.78%
Oct 22 70.53 69.72
70.74
69.5
1.2M 0.36%
Oct 21 70.28 69.99
70.81
69.56
1.6M 0.24%
Oct 18 70.11 69.7
70.13
69.29
1.5M 0.92%
Oct 17 69.47 70.28
70.28
69.34
933K -0.98%
Oct 16 70.16 70.24
70.9
69.94
1.4M -0.43%
Oct 15 70.46 70.12
70.52
69.53
1.1M 0.27%
Oct 14 70.27 70.4
70.77
69.96
1.1M -0.11%
Oct 11 70.35 69.64
70.58
69.25
807K 0.72%
Oct 10 69.85 69.8
69.88
68.95
979K 0.07%
Oct 9 69.8 68.95
69.95
68.34
1.6M 1.62%
Oct 8 68.69 69
69
68.03
1.7M -0.39%
Oct 7 68.96 69.2
69.26
68.36
840K -0.79%
Oct 4 69.51 68.49
69.58
67.76
1.3M 1.98%
Oct 3 68.16 69.58
69.81
68.1
1.4M -2.15%
Oct 2 69.66 69.66
69.85
68.52
1.1M -0.63%
Oct 1 70.1 70.66
70.74
69.81
1.2M -0.27%
Sep 30 70.29 70.58
71.24
69.91
1.4M -0.41%
Sep 27 70.58 70.55
71
70.24
1.1M 0.48%
Sep 26 70.24 69.21
70.33
68.7
1.3M 1.77%
Sep 25 69.02 69.03
69.54
68.12
1.7M -0.66%
Sep 24 69.48 69.13
69.65
67.75
2.2M 0.51%
Sep 23 69.13 70.3
70.92
69
2.1M -2.21%
Sep 20 70.69 71.82
71.82
70.09
3.4M -1.01%
Sep 19 71.41 71.75
72.07
70.42
2.9M 0.38%
Sep 18 71.14 70.87
71.58
70.11
2.2M 0.84%
Sep 17 70.55 70
71.64
68.83
4.6M 0.99%
Sep 16 69.86 77.53
78
69.6
10.6M -17.71%
Sep 13 84.9 84.43
85
83.95
1.2M 0.62%
Sep 12 84.38 84.83
85
83.91
1.5M -0.47%
Sep 11 84.78 84.72
84.94
83.43
1.5M -0.08%
Sep 10 84.85 84.48
85.64
83.69
2.0M 0.62%
Sep 9 84.33 84.28
84.84
83.45
1.7M 0.30%
Sep 6 84.08 85.33
86.04
83.73
1.6M -1.22%
Sep 5 85.12 90.01
90.01
84.89
2.4M -5.27%
Sep 4 89.86 91.19
92.05
87.68
3.7M -1.9%
Sep 3 91.6 91.21
92.81
90.85
2.0M 0.43%
Aug 30 91.21 91.46
92.35
89.95
1.4M -0.18%
Aug 29 91.37 90.6
93.04
90.29
1.5M 1.16%
Aug 28 90.32 90.7
91.31
89.97
988K 0%